NICE Orforglipron Appraisal: How Patient Experts Were Sought in the UK

In April 2026 the National Institute for Health and Care Excellence (NICE) asked for patient experts to share their lived experience of weight management as part of its technology appraisal of Orforglipron, a once daily oral GLP-1 medicine. That call closed on 20 April 2026. Since then the picture has moved on: the MHRA licensed Orforglipron in the UK as Foundayo on 10 August 2026, and the NICE appraisal is still in progress. This page keeps the original record and adds where things stand now.

The Official NICE Process

NICE is carrying out a technology appraisal. This is the rigorous, evidence-based procedure used in the UK to assess new medical treatments before they can be routinely recommended for use within the NHS.

As part of this assessment, patient experts are invited to participate. While clinical trial data provides vital statistics on safety and efficacy, patient experts offer the essential human context. They help the committee understand the daily reality of living with a condition and the practical limitations of currently available treatments.

What is Orforglipron?

Orforglipron is a medicine for weight management and type 2 diabetes, licensed in the UK by the MHRA as Foundayo on 10 August 2026. It belongs to a class of medications known as GLP-1 (glucagon-like peptide-1) receptor agonists.

Most medicines in this class (such as Mounjaro and the injectable form of Wegovy) are given by subcutaneous injection, whereas Orforglipron is a once daily oral tablet. According to the MHRA, dosing starts at 0.8 mg and steps up through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, with at least a month at each level. Whether it will be prescribed on the NHS depends on the NICE appraisal, which is still in progress.

Who may take part as a patient expert?

NICE is looking for individuals whose experiences align closely with the scope of the appraisal. This broadly includes:

• Patients living with higher weight (often guided by specific clinical BMI thresholds).
• Individuals managing related health impacts, such as cardiovascular risks or joint issues.
• Carers or family members who provide substantial support to someone meeting these criteria.

Crucially, applicants do not need to have taken Orforglipron. The committee seeks a deep understanding of the condition itself and the current landscape of weight management, rather than feedback on the specific drug.

The NICE Process Steps

Becoming a patient expert involves a structured, formal pathway:

• 1

  Expression of Interest

  Individuals review the NICE appraisal documents and submit a preliminary interest form via the official portal.

• 2

  Nomination Form

  Applicants complete a detailed nomination, outlining their lived experience and their motivation to contribute to public health guidance.

• 3

  Selection and Induction

  NICE selects candidates who best match the appraisal criteria. Those chosen receive comprehensive briefings and induction from the public involvement team.

• 4

  Committee Meeting Participation

  Patient experts attend formal virtual committee meetings, providing insight and answering questions alongside clinicians and health economists.

Community Discussion Context

Discussion of the NICE appraisal has also appeared on online forums such as Reddit. Community members frequently highlight regulatory updates and requests for public input. While this reflects public awareness and interest in the topic, community discussion does not replace official NICE or MHRA guidance. Patients must ensure they use official channels for medical facts and regulatory updates.

What this means for UK patients

The commencement of a NICE appraisal does not guarantee that a medicine will become available on the NHS. For Orforglipron, one of the two main hurdles has now been cleared:

• MHRA Licensing: Done. The Medicines and Healthcare products Regulatory Agency authorised Foundayo on 10 August 2026.
• NICE Recommendation: Still pending. The committee must conclude that the treatment represents a cost-effective use of NHS resources. NICE expects to publish its guidance on 18 November 2026.

NHS availability is not guaranteed, and the MHRA notes that Foundayo is not currently available via the NHS. Private prescribing through registered UK pharmacies is now possible. Patients should continue their current care plans and discuss any change with their healthcare providers.